Skip to main content

Table 3 General information and therapeutic outcomes on 5 patients with coexistent genetic alterations including EGFR, ROS1, and EML4-ALK in MPA and LA patients

From: A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients

Patients

1

2

3

4

5

Gender

Female

Male

Female

Male

Female

Age (years)

52

31

45

71

75

Smoking history

Never

Never

Never

Ever

Never

Lymphovascular invasion

Absent

Present

Absent

Absent

Absent

Tumor differentiation

Moderate

Moderate

Moderate

Moderate

Moderate

Stage

T1bN0M0

T1cN1M0

T1cN0M0

T1bN0M0

T1cN0M0

Pathological type

MPA

MPA

MPA

MPA

LA

Mutation status

ROS1+; EML4-ALK+

ROS1+; EML4-ALK+

EGFR L858R+; ROS1+

EGFR L858R+; ROS1+

EGFR 19-del+; ROS1+

Therapeutic intervention

Surgery; chemotherapy; crizotinib

Surgery; chemotherapy; crizotinib

Surgery; chemotherapy; EGFR inhibitors

Surgery; chemotherapy; EGFR inhibitors

Surgery; chemotherapy; EGFR inhibitors

Outcomes

Partial response

Partial response

Partial response

Recurrence

Partial response

  1. MPA micropapillary lung adenocarcinoma, LA lung adenocarcinoma without micropapillary component, EGFR+ EGFR mutation, ROS1+ ROS1 fusion, EML4-ALK+ EML4-ALK fusion